Biodexa PharmaceuticalsBDRX
13F holders, Q1 2025 (March 31)6holders +2
2new positions
0sold out
$1.32avg. 13F price*
At the end of Q1 2025, 6 institutions reported holding Biodexa Pharmaceuticals PLC (BDRX) in their 13F filings, up 2 from Q4 2024. 2 opened new positions and 0 sold out. The largest holders were UBS Group AG ($25K), GAMMA Investing LLC ($2K) and Morgan Stanley ($924).
- Company
- Biodexa Pharmaceuticals PLC
- CUSIP
- 59564R807
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $3K |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 14,072 shares bought, net +14,072 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| UBS Group AG | 0.00% | Add +167.2% | 18,832 | $25K |
| GAMMA Investing LLC | 0.00% | New | 1,426 | $2K |
| Morgan Stanley | 0.00% | New | 700 | $924 |
| Rhumbline Advisers | 0.00% | Add +104.5% | 315 | $414 |
| Contravisory Investment Management, Inc. | 0.00% | No change | 40 | $53 |
| SBI Securities Co., Ltd. | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is BDRX's weight in each manager's 13F, not the share of Biodexa Pharmaceuticals PLC the manager owns.